Clinical trial
Nivolumab Dose Optimization in Patients With a Complete, Partial or Stable…
NCT06116461 · Erasmus Medical Center, Other · Recruiting
Key facts
| NCT number | NCT06116461 |
|---|---|
| Title | Nivolumab Dose Optimization in Patients With a Complete, Partial or Stable Response |
| Official title | Nivolumab Dose Optimization in Patients With a Complete, Partial or Stable Response |
| Acronym | NIVOPTIMIZE |
| Lead sponsor | Erasmus Medical Center, Other |
| Status | Recruiting |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Melanoma |
| Intervention type | Drug |
| Interventions | Nivolumab |
| Enrollment | 34 |
| Start date | Jan 5, 2022 |
| Primary completion | Oct 1, 2024 |
| Completion | Jan 1, 2025 |
| First posted | Nov 3, 2023 |
| Last update posted | Apr 22, 2024 |
| Countries | Netherlands |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: